New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment.

Endocrine therapies that comprise anti-estrogens and aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive (ER+) (Luminal A) breast cancer-the most prevalent subtype. However, the emergence of resistance restricts their success by causing tumor relapse and re-growth, which demands a switch towards other therapeutic approaches in order to minimize or overcome resistance. Indeed, this clinical limitation highlights the search for new molecules to improve cancer treatment.

25(OH)D concentrations are not associated with adiposity indicators, but with the stage of immunodeficiency in people with HIV/AIDS.

Objective: this study assessed the association between serum 25(OH)D concentrations and anthropometric indicators of adiposity in people living with HIV/AIDS taking highly active antiretroviral therapy.

Methods: the study included 244 people living with HIV/AIDS who received outpatient care at the Institute of Tropical Diseases in the city of Teresina, Brazil. Sociodemographic, clinical, anthropometric and laboratory characteristics were examined.

Spectrum of offending drugs and cutaneous adverse drug reactions requiring hospitalisation in a tertiary South African hospital in TB/HIV endemic setting.

Introduction: Cutaneous immune-mediated adverse drug reactions are more prevalent in people with human immunodeficiency virus (PWH). Severe cutaneous adverse drug reactions (SCAR) are a life-threatening subset of cutaneous adverse drug reactions (CADRs) and a significant public health issue in settings endemic for human immunodeficiency virus and tuberculosis. However, limited data are available on CADR requiring hospitalisation in African settings.